Rationale for a T cell receptor peptide therapy in myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 998, Issue , 2003, Pages 320-323

  Jambou, F ^a   Menestrier, M ^a   Klingel Schmitt, I ^a   Caillat Zucman, S ^b   Aissaoui A ^a   Berrih Aknin, S ^a   Cohen Kaminsky, Sylvia ^a  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Myasthenia gravis; T cell receptor peptide therapy

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; HLA DR3 ANTIGEN; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; THREONYLPROLYLGLYCYLGLUTAMINYLGLYCYLLEUCYLGLUTAMINYLPHENYLALANYLLEUCYLPHENY LALANYLGLUTAMYLTYROSYLPHENYLALANYLSERYLGLUTAMYLTHREONYLGLUTAMINYLARGINYLASPARAGI NYLLYSYLGLYCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; STATISTICAL ANALYSIS; THYMUS HYPERPLASIA;

EID: 0141727692     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1254.035     Document Type: Conference Paper

References (5)

1. KUMAR, V. & E. SERCARZ. 1999. Distinct levels of regulation in organ-specific autoimmune diseases. Life Sci. 65: 1523-1530.
2. VANDENBARK, A.A. et al. 1996. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. J. Neurosci. Res. 43: 391-402.
3. VANDENBARK, A.A. et al. 1996. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. 2: 1109-1115.
4. TRUFFAULT, F. et al. 1997. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann. Neurol. 41: 731-741.
5. AÏSSAOUI, A. et al. 1999. Prevention of autoimmune attack by targeting specific T cell receptor in a SCID mice model of myasthenia gravis. Ann. Neurol. 46: 559-567.